Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Aug 2, 2022

ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

Jul 27, 2022

ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference

Jul 8, 2022

ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

Jun 27, 2022

PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA

Jun 22, 2022

ProMIS Neurosciences Announces Debt Amendment and Conversion

Jun 22, 2022

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

Jun 22, 2022

ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

May 17, 2022

ProMIS Neurosciences presents at the 2022 Neuro4D International Conference

May 13, 2022

ProMIS Neurosciences Announces First Quarter 2022 Results

May 13, 2022

ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …26
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy